Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

tDCS for Reducing the Incidence of OEI After Cesarean Section

29 aprile 2026 aggiornato da: Chaochao Zhong, Affiliated Hospital of Nantong University

Study on the Preventive and Therapeutic Effects and Mechanism of Transcranial Direct Current Stimulation on Morphine-Induced Itching After Cesarean Section: A Randomized Clinical Controlled Trial

Cesarean section is the most common obstetric surgery worldwide. Epidural anesthesia has become the preferred anesthesia method for cesarean sections due to its definite analgesic effect and minimal impact on mother and baby. To ensure postoperative analgesia, intrathecal administration of morphine (the preferred opioid for obstetric intrathecal analgesia) is a routine clinical protocol, but morphine-induced postoperative pruritus is a common adverse reaction. A study targeting the cesarean section population confirmed that the incidence of pruritus after epidural morphine administration is as high as 40%-75%.Transcranial direct current stimulation (tDCS) can enhance the activity of GABAergic inhibitory interneurons in the spinal dorsal horn through the cortical-spinal descending pathway, reverse the inhibitory effect of morphine on them, and restore negative feedback regulation of itch-specific GRPR⁺ neurons; at the same time, it downregulates the phosphorylation level and membrane expression of μ-opioid receptors in the spinal dorsal horn, weakening the receptor activation efficiency of morphine. On the other hand, tDCS can reduce peripheral nerve excitability, decrease mast cell degranulation in the skin, and reduce the release of histamine and tryptase; simultaneously, it inhibits the activation of glial cells in the spinal cord/cortex, decreases the secretion of pro-inflammatory factors such as TNF-α and IL-6, and blocks the vicious cycle of 'inflammation-receptor upregulation-itch exacerbation,' thereby reducing the occurrence of itch.This study aims to explore the effect of transcranial direct current stimulation (tDCS) on the incidence of morphine-induced itching after cesarean section by inhibiting the central itch perception circuits in cesarean section patients and antagonizing the disinhibitory effects mediated by μ-opioid receptors in the spinal dorsal horn.

Panoramica dello studio

Tipo di studio

Interventistico

Iscrizione (Stimato)

104

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  • ① Age 18-40 years, gestational age 37-41 weeks, singleton full-term pregnancy;

    • Planned elective or emergency cesarean section, using epidural anesthesia (0.1~0.2 mg/kg of morphine administered intrathecally during surgery);

      • American Society of Anesthesiologists (ASA) classification I-III;

        • Conscious and able to cooperate to complete scale assessments, serum sample collection, and postoperative follow-up;

          • Voluntarily participate in the study and sign the informed consent form.

Exclusion Criteria:

  • ① Presence of contraindications for tDCS (such as skull defects, intracranial metal implants, history of epilepsy, coagulation disorders);

    • Allergy to opioids or a history of severe OEI;

      • Presence of skin diseases (such as eczema, urticaria), liver diseases (cholestasis), mental disorders, or cognitive impairments;

        • Coexisting pregnancy complications (preeclampsia, gestational diabetes, autoimmune diseases);

          ⑤ Use of medications within the past week that may affect itch assessment, such as antihistamines, 5-HT3 receptor antagonists, or anti-inflammatory drugs.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Prevenzione
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Triplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore fittizio: control group (sham stimulation group)
Patients in the transcranial direct current stimulation (tDCS) group had the anode of the tDCS device placed over the left dorsolateral prefrontal cortex (F3 region) and the cathode over the right mastoid. tDCS was administered on the day of surgery (starting within 5 minutes after fetal delivery and terminating after the surgery upon transfer to the PACU). The current intensity was 1.5 mA. Patients in the sham stimulation group had the anode placed over the left dorsolateral prefrontal cortex (F3 region) and the cathode over the right mastoid, with a current of 1.5 mA applied only during the initial 30 seconds after stimulation begins, after which the current was reduced to 0 mA. All other procedures (electrode placement, stimulation duration, intervention frequency) were identical to the experimental group.
Sperimentale: Case group (tDCS group)
Patients in the transcranial direct current stimulation (tDCS) group had the anode of the tDCS device placed over the left dorsolateral prefrontal cortex (F3 region) and the cathode over the right mastoid. tDCS was administered on the day of surgery (starting within 5 minutes after fetal delivery and terminating after the surgery upon transfer to the PACU). The current intensity was 1.5 mA. Patients in the sham stimulation group had the anode placed over the left dorsolateral prefrontal cortex (F3 region) and the cathode over the right mastoid, with a current of 1.5 mA applied only during the initial 30 seconds after stimulation begins, after which the current was reduced to 0 mA. All other procedures (electrode placement, stimulation duration, intervention frequency) were identical to the experimental group.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Lasso di tempo
Incidence of itching within 24 hours after surgery (defined as VAS itching score ≥1)
Lasso di tempo: 24 hours after surgery
24 hours after surgery

Misure di risultato secondarie

Misura del risultato
Lasso di tempo
Incidence of itching at 12 and 48 hours postoperatively; VAS scores for itching at each time point; duration of itching and time of peak appearance
Lasso di tempo: 12 hours post-operation and 48 hours post-operation
12 hours post-operation and 48 hours post-operation
Number of times the analgesic pump was pressed and the doses of additional morphine within 48 hours postoperatively; VAS pain scores at 12, 24, and 48 hours postoperatively
Lasso di tempo: 12 hours, 24 hours, and 48 hours after surgery
12 hours, 24 hours, and 48 hours after surgery
Maternal adverse reactions (nausea and vomiting, drowsiness, dizziness, ear pain, skin erythema) incidence; neonatal 1-minute and 5-minute Apgar scores, birth weight, complications within 72 hours (jaundice, shortness of breath, feeding difficulties)
Lasso di tempo: Within 72 hours after surgery
Within 72 hours after surgery
Preoperative and postoperative 24h serum histamine, trypsin-like enzyme, TNF-α, IL-6, β-endorphin, and gastrin-releasing peptide precursor (ProGRP) levels
Lasso di tempo: 24 hours before surgery and 24 hours after surgery
24 hours before surgery and 24 hours after surgery

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 maggio 2026

Completamento primario (Stimato)

31 dicembre 2026

Completamento dello studio (Stimato)

20 febbraio 2027

Date di iscrizione allo studio

Primo inviato

23 aprile 2026

Primo inviato che soddisfa i criteri di controllo qualità

29 aprile 2026

Primo Inserito (Effettivo)

6 maggio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

6 maggio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

29 aprile 2026

Ultimo verificato

1 aprile 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Transcranial direct current stimulation

Sottoscrivi